Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598845 | 0.77 | SELE (0.33) | NOS1SMN1; SMN2 | |
| SCHEMBL29565259 | 0.73 | NCF1 (0.38) | NOS1KITPIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL29565017 | 0.72 | NCF1 (0.37) | NOS1KITPIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL29564560 | 0.72 | NCF1 (0.37) | NOS1KITPIK3CDPIK3CAPIK3CB | |
| SCHEMBL30808060 | 0.71 | IKBKB (0.53) | NOS1KITPI4KAPI4KB | |
| SCHEMBL18312205 | 0.71 | IKBKB (0.53) | NOS1KITPI4KAPI4KB | |
| SCHEMBL10771693 | 0.69 | IKBKB (0.45) | NOS1UHRF1SMN1; SMN2 | |
| SCHEMBL14257473 | 0.66 | LRRK2 (0.35) | GRIN3BGRIN1GRIN2C | |
| SCHEMBL14871305 | 0.65 | KIT (0.44) | KIT | |
| SCHEMBL31637623 | 0.65 | BACE1 (0.43) | NOS1BACE1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019214546-A1 | FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, IRAK4 | NOS1 594/4885UHRF1 2870/4885KIT 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.